ARTHEx Biotech Secures $87M to Advance RNA Medicines

Sep 17, 2025
ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million to advance its lead program ATX-01 for Myotonic Dystrophy Type 1.

ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million, announced in a press release. The funding was led by new investor Bpifrance, with participation from existing shareholders such as AdBio Partners and Columbus Venture Partners.

The proceeds will be used to further the global clinical development of ARTHEx's lead program, ATX-01, which targets Myotonic Dystrophy Type 1 (DM1). ATX-01 is an anti-miR oligonucleotide designed to inhibit microRNA23b (miR-23b), a natural repressor of MBNL protein expression. This mechanism aims to increase MBNL production, decrease toxic DMPK mRNA, and improve splicing abnormalities in DM1 patients.

The financing will support the ongoing interventional Phase I/IIa ArthemiRTM study and prepare for an open-label extension to support a registrational study, further advancing ARTHEx's pipeline of targeted RNA medicines.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.